Background. Amphotericin B is a widely used broad-spectrum antifungal agent, despite being associated with significant adverse events, including nephrotoxicity.
Amphotericin B (AmB) has broad activity against a wide range of fungi, although its use is frequently limited by an unfavorable safety profile, most notably doselimiting nephrotoxicity [1] [2] [3] [4] . Renal failure related to receipt of AmB has been associated with higher mortality rates, an increased length of stay in the hospital, and an increased total cost of health care [5] [6] [7] [8] [9] [10] [11] [12] [13] .
The aim of the present study was to evaluate issues consent were obtained in compliance with the local policy in each country. A multidisciplinary panel served in an advisory role throughout this study. The study was designed to collect demographic, clinical outcome, and resource utilization data on hospitalized patients who had either proven, probable, or possible fungal infections [14] or suspected invasive fungal infections that were treated with the use of either AmB-d or one of its lipid formulations. The lipid formulations used in the study were amphotericin B lipid complex (ABLC); amphotericin B colloidal dispersion (ABCD); and liposomal amphotericin B (L-AmB). ABLC (in Germany) and ABCD (in Germany, Spain, and the United Kingdom) were only available through an international pharmacy at the time of the study.
Patients who were 18-80 years of age and who had received a full course of AmB either for treatment of a fungal infection or as empirical antifungal therapy were eligible to participate in the study. Patients who qualified for inclusion in the study during multiple stays in the hospital were enrolled in the study only once. Patients were excluded if they failed to meet all of the inclusion criteria or if the opinion of the investigator dictated exclusion.
Data collection. All patients were observed from initiation of AmB therapy until discharge from the hospital. Demographic information, as well as data on relevant clinical outcomes and resource utilization, were collected at the time that the single episode of care occurred. Data were entered into a database via the Internet. Data quality was monitored during data entry and by queries from the coordinating center to the investigators.
Clinical outcome definitions. Clinical response to therapy was evaluated by the individual investigator, by use of protocolpredefined definitions, and a patient was considered to be "responding" to treatment if a complete response or a partial response was observed. "Failure" of therapy was defined by stable disease, therapeutic failure, relapse, or death. Another classification, "indeterminate outcome," was used to describe patients who survived but had an indeterminate outcome. If microbiological data were available, then a microbiological response was defined as either eradication, persistence, or relapse of infection or as an indeterminate outcome. A patient was classified as having normal renal function at baseline if the last serum creatinine clearance noted before initiation of treatment with AmB products in the present study was within the sexspecific range considered to be normal at the institution or if the creatinine clearance was у90 mL/min according to use of the Cockroft-Gault formula with body weight at baseline. Nephrotoxicity, or worsening of renal function, was defined as a у50% increase in the peak serum creatinine level from baseline during AmB treatment, and it was graded as slight (50%-99% increase), moderate (100%-199% increase), or severe (у200% increase). Length of hospital stay was calculated as the number of days that the patient stayed in the hospital after initiation of AmB treatment.
Statistical analyses. The key demographic and clinical characteristics at hospital admission were compared using the test or Fisher's exact test for proportions. Continuous data 2 x are presented as mean (‫ע‬SD) values. A 3:1 ratio was used to convert dosages of a lipid-based formulation to equivalent dosages of conventional formulations for all patients [15] [16] [17] . An initial dose of AmB (per kilograms of body weight before initiation of treatment) was dichotomized using thresholds of 3.0 mg/kg and 0.9 mg/kg for lipid-based and non-lipid-based formulations, respectively. Patients were stratified according to renal function at the time of initiation of AmB treatment. Factors associated with the onset of nephrotoxicity and with mortality were assessed using multiple logistic regression analyses. Factors associated with time to discharge from the hospital were estimated using Cox proportional hazards models. Time to discharge from the hospital was censored at death from an etiologic (i.e., time to discharge censored at death) perspective and was uncensored at death from an accounting (i.e., time to discharge uncensored at death) perspective. The etiologic perspective is that of a researcher interested in cause and effect (i.e., whether nephrotoxicity influences length of stay in the hospital, provided that death does not occur). The accounting perspective is that of a hospital manager thinking in monetary terms. Forward and backward variable-selection procedures were used to assist in the identification of study variables. The final models included all statistically significant and/ or clinically significant terms, plus age and sex, plus factors confounding individually or jointly. Stata/SE software, version 7.0 (Stata), and SAS software, version 8.00 (SAS), were used for the analyses.
RESULTS
A total of 428 patients were enrolled in the present trial. After 10 of these patients were excluded because of missing serum creatinine values, 418 evaluable patients remained. Twentyeight patients (7%) had abnormal kidney function at baseline. The serum creatinine level worsened (by у50%) in 7 patients (25%), and 11 (39%) of the 28 patients who had abnormal renal function at baseline died. A total of 390 patients (93%) had normal kidney function at baseline. For these patients, we present a detailed account of the factors associated with worsening of kidney function, mortality, and total length of stay in the hospital.
Clinical and microbiological characteristics and regimens. The main demographic and clinical characteristics of the study participants are listed in table 1. There was a trend toward initial use of lipid formulations for the treatment of patients with abnormal, compared with normal, renal function at baseline (54% vs. 37% of patients;
). P p .08 Normal renal function at baseline was defined by a serum creatinine level, determined before initiation of treatment with amphotericin B products in the present study, that was within the sex-specific range considered to be normal at the institution or by a creatinine clearance of у90 mL/min, as determined using the Cockroft-Gault formula with the body weights of the patients at initiation of amphotericin B treatment.
Isolates were recovered from 88 patients. Candida species were isolated from 40 patients, Aspergillus species from 28 patients, Cryptococcus species from 4 patients, and Histoplasma species from 1 patient. Fifteen fungal isolates were not further specified. The majority of patients (47 patients) received treatment with AmB-d, 33 were treated with L-AmB, and 8 were receiving either ABLC or ABCD. There was no particular excess of any specific type of fungal infection noted in any treatment group.
The majority of patients in Germany (87%), the United of AmB-associated adverse events was given to 84% of patients who initially received AmB-d, compared with 47% of patients who initially received any of the lipid formulations ( ), P ! .001 and pretreatment included volume loading for 25% and 3% of these patients, respectively. Thirty-six percent of patients who initially received therapy with AmB-d had therapy switched to lipid formulations of AmB, primarily because of renal toxicity (46% of patients), other adverse events attributed to AmB (41.3%), lack of response (4%), or other reasons (9%).
Clinical response and microbiological outcomes. A total of 225 patients (53.8%) had a complete or partial response to antifungal therapy. For 90 patients (21.5%), the outcome was indeterminate, and 101 patients (22.4%) experienced treatment failure. Of the patients who experienced treatment failure, 78.2% died. A total of 108 patients (47.3%) who experienced nephrotoxicity while receiving treatment with AmB products had treatment failure. The overall favorable response of 55.8% was higher among patients without impaired renal function.
The number of patients with abnormal renal function at baseline who had therapeutic success with AmB-d, ABCD or ABLC, and L-AmB were 6 (46.2%) of 13 patients, 2 (50.0%) of 4 patients, and 8 (72.7%) of 11 patients, respectively. The microbiological response in patients in whom fungal infection was proven or probable ( ) was eradication (in 38.5% of n p 91 patients), persistency (in 8.8%), or indeterminate (in 52.7%).
Worsening of renal function. Before initiation of AmB therapy, serum creatinine levels were stable or decreasing in 342 (82%) of the evaluable 418 patients. There were 390 patients with normal renal function at baseline who were at risk of developing abnormal renal function. Of these patients, 246 (63%) initiated therapy with AmB-d, and 144 (37%) initiated therapy with AmB lipid formulation. An increase in the serum creatinine level after any exposure to an AmB formulation was observed in 85% of patients. Nephrotoxicity developed in 221 patients (57%). The rate of worsening of renal function was dependent on the AmB formulation received (table 3) .
Pretreatment for the prevention of AmB-related adverse events was given to 84% of patients who initiated treatment with AmB-d, compared with 49% of those who initiated treatment with the other formulation ( ). Kidney-sparing P ! .001 pretreatments (volume loading and hydration) only numerically reduced nephrotoxicity in multivariate analyses. Concomitant nephrotoxins included aminoglycosides (in 41% of patients), immunosuppressants (in 25%), and cytotoxic agents (in 24%). When controlled for cofactors, 10 additional days of treatment with AmB nearly doubled the risk of nephrotoxicity developing ( ). Use of immunosuppressants also resulted P ! .001 in an approximately doubled risk ( ) (tables 4-6). An-P p .035 alyzing the association between nephrotoxicity and mortality, we found that 53% of patients who developed severe nephrotoxicity died, compared with only 18% of patients who did not develop nephrotoxicity.
Length of hospital stay. From both the etiologic and the accounting perspectives, increases of у50% in the serum creatinine level were associated with a longer hospital stay among the 390 patients who had normal kidney function at baseline. From an etiologic perspective, for the groups with or without worsening of renal function, the average length of stay in the hospital was estimated to be 33.8 days (95% CI, 28.9-38.7 days) and 25.2 days (95% CI, 22.3-28.2 days), respectively, for a difference of 8.6 days (95% CI, 2.4-14.7 days;
). From P p .006 an accounting perspective, the 2 groups stayed in the hospital for an average of 27.0 days (95% CI, 24.3-29.8 days) and 21.7 days (95% CI, 19.4-24.0 days), respectively, for a difference of 5.3 days (95% CI, 1.6-9.1 days; ) (figure 1). P p .004 For the 28 patients with abnormal renal function, there was Nephrotoxicity among patients, by formulation of amphotericin B received, overall length of stay in the hospital, and 
NOTE. Data are no. (%) of patients, unless otherwise indicated. Nephrotoxicity was defined by a serum creatinine value that was 11.5 times greater than the serum creatinine value noted at baseline, and it was further subdivided into 3 categories on the basis of severity: slight (a serum creatinine level 11.5-2 times that noted at baseline), moderate (a serum creatinine level 2-3 times that noted at baseline), and severe (a serum creatinine level 13 times that noted at baseline). ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; AmB-d: amphotericin B deoxycholate; L-AmB, liposomal amphotericin B; LOS, length of stay.
a Normal renal function at baseline was defined by a serum creatinine level, determined before initiation of treatment with amphotericin B products in the present study, that was within the sex-specific range considered to be normal at the institution or by a creatinine clearance of у90 mL/min, as determined using the Cockroft-Gault formula with the body weights of the patients at initiation of amphotericin B treatment. a significant difference in the length of stay in the hospital, compared with patients with stable renal function ( ). The P p .036 assessment by the investigator regarding other adverse events attributable to different amphotericin B formulations is shown in table 7. For the 82 patients with normal renal function who died during their hospital stay, a length of stay of 25.6 days versus 23.6 days, as well as the difference in length of stay between the groups of patients with or without worsening of renal function, was not significant ( ). The mean length of stay in the P p .847 hospital, according to the AmB formulation received, was dependent on mortality and nephrotoxicity (table 3) .
The effect of worsening kidney function on increased hospital stay was homogeneous throughout the study population. Controlling for cofactors and the severity of nephrotoxicity did not affect these estimates. Slight, moderate, and severe nephrotoxicity; allogeneic stem cell transplantation; and treatment for documented fungal infection were independently and significantly associated with a longer hospital stay (table 4) .
Mortality. Of the 390 patients without renal impairment at baseline, 82 patients (21%) died. Patients with or without worsening of kidney function during receipt of AmB therapy had a crude mortality rate of 24% and 18% ( ), re-P p .17 spectively. After adjustment for age, sex, underlying medical condition, and likelihood of presence of fungal infection, patients whose serum creatinine level increased by у200% above pretreatment levels were 6.3 times (95% CI, 2.7-14.5) more likely to die than were patients whose serum creatinine level either increased by !50% or decreased with treatment. In addition, patients who underwent allogeneic stem cell transplantation, had relapse of leukemia or lymphoma, or had proven fungal infection had particularly poor prognoses (tables 4-6). Although overall mortality was not driven by nephrotoxicity, development of severe nephrotoxicity ( ) and duration P ! .001 of therapy for documented fungal infection ( ) were P p .012 significant predictors of death in a logistic regression model (table 5) .
Other adverse events and hospital-resource use. The assessment by the investigator regarding other adverse events NOTE. Nephrotoxicity was defined by a serum creatinine value that was 11.5 times greater than the serum creatinine value noted at baseline, and it was further subdivided into 3 categories on the basis of severity: slight (a serum creatinine level 11.5-2 times that noted at baseline), moderate (a serum creatinine level 2-3 times that noted at baseline), and severe (a serum creatinine level 13 times the serum creatinine value noted at baseline, and it was further subdivided into 3 categories on the basis of severity: slight (a serum creatinine level 11.5-2 times that noted at baseline), moderate (a serum creatinine level 2-3 times that noted at baseline), and severe (a serum creatinine level 13 times that noted at baseline ) of patients, respectively. These adverse events lead to the consumption of additional hospital health care resources, which directly influenced the overall costs of hospital care for these patients. Additional medical services included 727 additional laboratory procedures performed to assess body fluids and tissues and conduct therapeutic drug monitoring, 65 additional imaging tests (including endoscopy and imaging), 9 separate episodes of dialysis for 2 patients, and 226 additional in-patient consultations provided by either primary care physicians or specialists for adverse events. An additional 2283 medications (average number of medications received per patient, 5.5) and 220 other medical services were used in the treatment or prevention of AmB-associated adverse events.
DISCUSSION
The present study prospectively evaluated the clinical and outcomes data associated with the use of different parenteral formulations of AmB in the routine care of patients in Europe, as well as the economic implications of such data. Our analyses suggest that lower thresholds of increases in the serum creatinine level (i.e., increases of у50%) are associated with a significantly longer stay in the hospital than has been previously reported. AmB-attributable severe nephrotoxicity is strongly associated with an excess number of deaths and longer hospital stay.
Despite the current era of new antifungal agents that have improved safety profiles, emerging breakthrough fungal infections have been reported [18] [19] [20] . Therefore, different formulations of AmB remain of interest in the treatment of invasive fungal infections. The advent of antifungal agents with improved tolerability also increases the desirability of having an improved understanding of the characteristics of an unselected patient population receiving AmB formulations and of the factors associated with their prognosis and use of resources.
The inclusion criteria were purposefully broad, in that patients with normal and abnormal renal function who were receiving the drug for various invasive fungal diseases were enrolled to study the effect of the drug in everyday settings. The Table 6 . Predictors of length of stay in the hospital for patients with normal renal function at baseline. times the serum creatinine value noted at baseline, and it was further subdivided into 3 categories on the basis of severity: slight (a serum creatinine level 11.5-2 times that noted at baseline), moderate (a serum creatinine level 2-3 times that noted at baseline), and severe (a serum creatinine level 13 times that noted at baseline). e Reference standard.
rate of nephrotoxicity was highest for patients in the group receiving AmB-d, and the reasons for switching therapy to the use of AmB lipid formulations were mostly related to the development of renal-associated adverse events. Although not all nephrotoxicity observed in the present study may be attributable to AmB agents alone, it is interesting to note that, before initiation of AmB, serum creatinine levels were stable or improving in 83% of patients who had increased levels observed later; this finding suggests that AmB formulations were frequently related to deterioration of renal function. The duration of AmB therapy, choice of formulation for use as initial therapy (with AmB-d being a stronger predictor than lipid formulations), and coadministration of immunosuppressants were significant predictors for the development of nephrotoxicity in our population. These variables have also been confirmed as predictors of nephrotoxicity in other studies [10, 21, 22] . This is an important consideration in the selection of firstline therapy, because switching therapy to an antifungal agent associated with less renal toxicity may not improve existing renal impairment [23] .
We did not find that aminoglycosides, chemotherapy, underlying condition, sex, and age predicted the development of nephrotoxicity in our patient population, as they did in some other studies [24, 25] . In addition, although sodium supplementation and hydration can be used to prevent nephrotoxicity [26] [27] [28] [29] , our study did not confirm the efficacy of volume loading in preventing nephrotoxicity. These counterintuitive findings may be the result of residual confounding introduced by careful channeling of type and dose of concomitant nephrotoxic medication or nephroprotective measures instituted to ensure the best outcomes for patients who were receiving highly nephrotoxic AmB products [6, 30] .
Another important finding of the present study was that, for patients with severe nephrotoxicity, the odds of death occurring increased by 15-fold, compared with patients who did not experience nephrotoxicity, as reported elsewhere [5] . The mortality rate was associated with underlying disease ( ) P p .051 and the level of certainty of fungal infection.
The present study focused on patients with normal renal function at baseline. In this population, nephrotoxicity significantly increased the length of stay in the hospital, according to the accounting and etiological perspectives. This is consistent with some reports [11, 31, 32] but not with others [12, 33] . Some of these conflicting findings may be explained by the report of an incident of renal damage as opposed to prevalent renal damage. Patients who already had poor kidney function before receiving AmB products (9% of patients) faced extended stays in the hospital. In addition, death masked a trend toward a hospital stay that was 3.3 days longer for patients who developed renal impairment, compared with patients who did not develop renal impairment. Our findings are not surprising: the upper limit of the range of serum creatinine levels considered to be normal already can indicate a glomerular filtration rate as low as 50 mL/min.
The incremental costs associated with AmB-induced renal impairment have been studied by numerous groups [11, 32, 33] . We focused on the length of the hospital stay, because it was not feasible to make a direct assessment of the economic aspects of nephrotoxicity because of different and changing hospital reimbursement policies in different countries. Patients with nephrotoxicity were hospitalized longer than patients without nephrotoxicity; this occurred independently of the underlying condition. Given the prevalence of AmB-associated nephrotoxicity, this finding has important repercussions for overall resource utilization in institutions where AmB formulations are widely used.
The present study had certain limitations, including the fact that the definition of nephrotoxicity will influence the results. Data on nephrotoxicity and length of stay in the hospital for patients with normal kidney function at baseline. It was estimated that, at any given time, the number of patients without nephrotoxicity who were still hospitalized was 24% (95% CI, 5%-38%) and 32% (95% CI, 14%-47%) lower, from an accounting perspective and an etiologic perspective, respectively, than the number of patients with nephrotoxicity who were still hospitalized. Dashed lines denote a у50% increase in the serum creatinine level, compared with the pretreatment level; solid lines denote either an increase of !50% in the serum creatinine level or no increase. AmB, amphotericin B. a Categories with !1% incidence were collapsed into 1 category ("Other"). b Other clinical adverse events included bone pain, bronchospasm, chills, edema, febrile crisis, fever, headache, hypotension, hypoxia, pruritus, nausea, pain in the upper or lower extremities, peripheral edema, rash, rigors, tachycardia, and vomiting.
The incidence of nephrotoxicity during receipt of treatment with AmB has been shown to vary by definition and by study [6, 7, 9, 31, 34, 35] . All of these studies used AmB-d, and the majority excluded patients who had underlying renal impairment. The definition of nephrotoxicity can create important differences in all outcome variables [36] . Although we defined nephrotoxicity as a у50% increase in the serum creatinine level at baseline, another study defined it as a у100% increase, which would mean that patients considered to have nephrotoxicity on the basis of our definition would be included in the com-parator group [10] . Another study using the same increment as ours also found nephrotoxicity to be associated with a longer baseline length of stay in the hospital and higher mortality [11] . The present study demonstrated that the use of AmB contributed to worsening kidney function, which was strongly associated with an excess number of deaths and a longer stay in the hospital. Measures to decrease the frequency of AmB-related toxicity by use of newer and less-toxic antifungal agents could result in an improvement in treatment outcomes and decreased resource utilization.
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